{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:46:56Z","timestamp":1792111616371,"version":"4.4.0"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"09","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deutsche\n                        Forschungsgemeinschaft","award":["EXC 2145 SyNergy ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy ID 390857198"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Demenz mit Lewy-K\u00f6rperchen (DLB) ist nach der Alzheimer-Demenz die\n                    zweith\u00e4ufigste neurodegenerative Demenzform und z\u00e4hlt zu den atypischen\n                    Parkinson-Syndromen. Sie ist charakterisiert durch kognitive Fluktuationen,\n                    visuelle Halluzinationen, eine REM-Schlaf-Verhaltensst\u00f6rung und\n                    Parkinson-Symptome. Typischerweise treten die kognitiven Einbu\u00dfen vor oder bis\n                    maximal ein Jahr nach Beginn der motorischen Symptomatik auf\n                    (\u201eEinjahreskriterium\u201c). Neuropathologisch liegt eine \u03b1-Synukleinopathie mit\n                    Lewy-K\u00f6rperchen in Neuronen vor, h\u00e4ufig begleitet von Kopathologien. Die\n                    Diagnosestellung erfolgt klinisch nach den McKeith-Kriterien unter Einbeziehung\n                    z.B. bildgebender Biomarker. Therapeutisch stehen symptomorientierte Ans\u00e4tze im\n                    Vordergrund. Krankheitsmodifizierende Therapien stehen bislang nicht zur\n                    Verf\u00fcgung, werden jedoch in Therapiestudien erprobt. Die Entwicklung biologisch\n                    definierter Diagnosekriterien und molekularer Biomarker ist zentral f\u00fcr\n                    zuk\u00fcnftige Therapiestudien.<\/jats:p>","DOI":"10.1055\/a-2791-7810","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:31:31Z","timestamp":1782340291000},"page":"340-350","source":"Crossref","is-referenced-by-count":1,"title":["Demenz mit Lewy-K\u00f6rperchen"],"prefix":"10.1055","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9980-9981","authenticated-orcid":false,"given":"Lena","family":"Marth","sequence":"additional","affiliation":[{"name":"Neurologische Klinik, LMU Klinikum, Ludwigs-Maximilians-Universit\u00e4t\n                    M\u00fcnchen (LMU), M\u00fcnchen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE), M\u00fcnchen,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8lina","family":"Lund","sequence":"additional","affiliation":[{"name":"Neurologische Klinik, LMU Klinikum, Ludwigs-Maximilians-Universit\u00e4t\n                    M\u00fcnchen (LMU), M\u00fcnchen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE), M\u00fcnchen,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[{"name":"Neurologische Klinik, LMU Klinikum, Ludwigs-Maximilians-Universit\u00e4t\n                    M\u00fcnchen (LMU), M\u00fcnchen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE), M\u00fcnchen,\n                    Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy), M\u00fcnchen,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[{"name":"Neurologische Klinik, LMU Klinikum, Ludwigs-Maximilians-Universit\u00e4t\n                    M\u00fcnchen (LMU), M\u00fcnchen, Germany"},{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen (DZNE), M\u00fcnchen,\n                    Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy), M\u00fcnchen,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report\n                    of the DLB Consortium","volume":"89","author":"I G McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"T F Outeiro","year":"2019","journal-title":"Mol Neurodegener"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"H Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.26191","article-title":"Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic\n                    review","volume":"30","author":"M Petrou","year":"2015","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"107255","DOI":"10.1016\/j.parkreldis.2024.107255","article-title":"The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body\n                    dementia: A systematic review","volume":"131","author":"J H Tan","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/bpa.12424","article-title":"TDP-43 pathology in Alzheimer\u2019s disease, dementia with Lewy bodies and\n                    ageing","volume":"27","author":"K E McAleese","year":"2017","journal-title":"Brain Pathol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jnen\/nlx007","article-title":"Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel\n                    Insights Into Brain Aging and Neurodegenerative Diseases","volume":"76","author":"G G Kovacs","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e14191","DOI":"10.1002\/alz.14191","article-title":"Lewy body co-pathology in Alzheimer\u2019s disease and primary age-related tauopathy\n                    contributes to differential neuropathological, cognitive, and brain atrophy\n                    patterns","volume":"21","author":"F C Almeida","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.parkreldis.2014.02.012","article-title":"Concomitant pathologies among a spectrum of parkinsonian disorders","volume":"20","author":"B N Dugger","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1017\/cjn.2016.2","article-title":"The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic\n                    Review","volume":"43","author":"D B Hogan","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000271090.28148.24","article-title":"Mixed brain pathologies account for most dementia cases in community-dwelling\n                    older persons","volume":"69","author":"J A Schneider","year":"2007","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-021-01121-w","article-title":"Contribution of rare homozygous and compound heterozygous VPS13C missense\n                    mutations to dementia with Lewy bodies and Parkinson\u2019s disease","volume":"9","author":"S Smolders","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.3390\/ijms26083578","article-title":"GWAS by Subtraction to Disentangle RBD Genetic Background from\n                    \u03b1-Synucleinopathies","volume":"26","author":"A Gaudio","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s\n                    Association Workgroup","author":"C R Jack","journal-title":"Alzheimers Dement"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"fcae162","DOI":"10.1093\/braincomms\/fcae162","article-title":"Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally\n                    well as amyloid PET","volume":"6","author":"S De Meyer","year":"2024","journal-title":"Brain Commun"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/psyg.13101","article-title":"Donepezil for dementia with Lewy bodies: meta-analysis of multicentre,\n                    randomised, double-blind, placebo-controlled phase II, III, and, IV studies","volume":"24","author":"E Mori","year":"2024","journal-title":"Psychogeriatrics"},{"key":"ref17","first-page":"1611","article-title":"Cholinesterase inhibitors and memantine for Parkinson\u2019s disease dementia and\n                    Lewy body dementia: A meta-analysis","volume":"17","author":"Y-H Meng","year":"2019","journal-title":"Exp Ther Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1017\/S1041610218001400","article-title":"Management of visual hallucinations in dementia and Parkinson\u2019s disease","volume":"31","author":"P Swann","year":"2019","journal-title":"Int Psychogeriatr"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/mds.28960","article-title":"High Pesticide Exposure Events and Dream-Enacting Behaviors Among US\n                    Farmers","volume":"37","author":"Y Yuan","year":"2022","journal-title":"Mov Disord"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/ene.15698","article-title":"Mediterranean diet is associated with a lower probability of prodromal\n                    Parkinson\u2019s disease and risk for Parkinson\u2019s disease\/dementia with Lewy bodies:\n                    A longitudinal study","volume":"30","author":"M I Maraki","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00415-023-12033-1","article-title":"High intake of ultra-processed food is associated with dementia in adults: a\n                    systematic review and meta-analysis of observational studies","volume":"271","author":"A E Henney","year":"2024","journal-title":"J Neurol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnen\/nly065","article-title":"Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact\n                    Sports","volume":"77","author":"J W Adams","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2024.4643","article-title":"Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum","volume":"82","author":"D Ferreira","year":"2025","journal-title":"JAMA Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1002\/alz.14118","article-title":"Long-term effects of cholinesterase inhibitors and memantine on cognitive\n                    decline, cardiovascular events, and mortality in dementia with Lewy bodies: An\n                    up to 10-year follow-up study","volume":"20","author":"H Xu","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e70275","DOI":"10.1002\/alz.70275","article-title":"Sex differences in prodromal dementia with Lewy bodies using the National\n                    Alzheimer\u2019s Coordinating Center data","volume":"21","author":"K A Wyman-Chick","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e70134","DOI":"10.1002\/trc2.70134","article-title":"A common outcome set for trials in dementia with Lewy bodies (DLB COS)","volume":"11","author":"JP M Kane","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3233\/JAD-240327","article-title":"Digital Biomarkers for the Assessment of Non-Cognitive Symptoms in Patients with\n                    Dementia with Lewy Bodies: A Systematic Review","volume":"100","author":"N S Sjaelland","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00401-025-02853-y","article-title":"A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a\n                    progression marker for Parkinson\u2019s disease","volume":"149","author":"A M Bernhardt","year":"2025","journal-title":"Acta Neuropathol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research\n                    diagnostic criteria","volume":"23","author":"G U H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e70470","DOI":"10.1002\/alz.70470","article-title":"Implications and opportunities regarding biological frameworks in overt and\n                    prodromal dementia with Lewy bodies","volume":"21","author":"J G Goldman","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","article-title":"Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s\n                    and related diseases","volume":"112","author":"H Endo","year":"2024","journal-title":"Neuron"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-024-00787-9","article-title":"Positron emission tomography tracers for synucleinopathies","volume":"20","author":"J Xiang","year":"2025","journal-title":"Mol Neurodegener"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"I G McKeith","year":"2020","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research\n                    diagnostic criteria","volume":"23","author":"G U H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: towards an integrated\n                    staging system for research","volume":"23","author":"T Simuni","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/mds.28879","article-title":"Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized,\n                    Placebo-Controlled Trial","volume":"37","author":"K Biglan","year":"2022","journal-title":"Mov Disord"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.14283\/jpad.2024.36","article-title":"Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of\n                    Neflamapimod in Dementia with Lewy Bodies","volume":"11","author":"N D Prins","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e12296","DOI":"10.1002\/trc2.12296","article-title":"Safety, target engagement, and biomarker effects of bosutinib in dementia with\n                    Lewy bodies","volume":"8","author":"F L Pagan","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"A Migdalska-Richards","year":"2016","journal-title":"Ann Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease","volume":"387","author":"G Pagano","year":"2022","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"104021","DOI":"10.1016\/j.ebiom.2022.104021","article-title":"Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b\n                    with exposure levels sufficient for therapeutic efficacy in a murine Parkinson\n                    model: A randomised, double-blind, placebo-controlled phase 1a trial","volume":"80","author":"J Levin","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2791-7810.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:16:24Z","timestamp":1792109784000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2791-7810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":41,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2791-7810","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}